Trevi Therapeutics (TRVI) Stock Price, Quote, News & History | Benzinga

Trevi Therapeutics Inc (TRVI) Stock Price, Quote, News & History

TRVINASDAQ

Trade with Public

Trade with Public

$17.92

-0.03-0.17%

At close: Aug 25, 5:00 PM EST

$17.92

-0.03-0.17%

Pre-Market: 4:23 AM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

-

Close

$17.92

Volume / Avg.

41.00 / 2.07M

Day Range

- - -

52 Wk Range

6.93 - 20.22

Market Cap

$2.55B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

48

Short Interest

9.86%

Days to Cover

7.83

Recent Trevi Therapeutics, Inc. News

This Fortinet Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Tuesday

Wall Street analysts upgraded Fortinet, Goldman Sachs, Adaptive Biotechnologies, and Five Below, with positive outlooks and raised price targets.

Avi Kapoor

This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Top Wall Street analysts change outlook on top stocks. For analyst rating changes, see https://www.benzinga.com/analyst-stock-ratings. INSM initiated with $192 PT.

Avi Kapoor

Global Payments To Rally More Than 28%? Here Are 10 Top Analyst Forecasts For Monday

Wall Street analysts change ratings for FITB, TRVI, JAZZ, GPN, EAT, URBN, MNST. See full list on benzinga.com/analyst-stock-ratings

Avi Kapoor

ManpowerGroup Posts Upbeat Q2 Earnings, Joins Docebo, Zentalis Pharmaceuticals And Other Big Stocks Moving Higher On Friday

US stocks lower, Nasdaq falls 400 pts. ManpowerGroup shares rise after upbeat earnings. Other big gainers: PHOE, SG, TRVI, DCBO, ZNTL, GPRE, SLS, FEIM, TRV, BHVN, KOS, BJRI, MBX.

Avi Kapoor

What's Going On With Trevi Therapeutics Stock?

Trevi Therapeutics shares are trading higher after it announced pricing of its $150 million offering of 11.6 million shares at $13 per share.

Alex Perry

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-52.63M

Investing Cash Flow (TTM)

-176.62M

Financing Cash Flow (TTM)

166.49M

Free Cash Flow (TTM)

-52.87M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

-62.76M

Analyst Trends and Forecast

6

Mar

1

Apr

3

May

3

Jul

3

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$2.24B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

7.95

Earnings Yield % (TTM)

-1.95%

Earnings Yield % (FWD)

-2.45%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$2.26

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

$0

Total Cash

$54.30M

Debt to Equity

0.00

Issuance of Debt (TTM)

$0

Repayment of Debt (TTM)

$0

Key Statistics

Open

-

Close

$17.92

Volume / Avg.

41.00 / 2.07M

Day Range

- - -

52 Wk Range

6.93 - 20.22

Market Cap

$2.55B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

48

Short Interest

9.86%

Days to Cover

7.83

About

Sector

Health Care

Industry

Pharmaceuticals

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary f...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Trevi Therapeutics (TRVI) stock?

A

You can purchase shares of Trevi Therapeutics (NASDAQ:TRVI) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Trevi Therapeutics (TRVI) competitors?

A

Other companies in Trevi Therapeutics’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).

Q

What is the forecast, or price target, for Trevi Therapeutics (TRVI) stock?

A

Trevi Therapeutics has a consensus price target of $22.28.

Q

What is the current price for Trevi Therapeutics (TRVI)?

A

The stock price for Trevi Therapeutics (NASDAQ: TRVI) is $17.92 last updated August 26, 2026 at 4:00 PM EDT.

Q

Does Trevi Therapeutics (TRVI) pay a dividend?

A

There are no upcoming dividends for Trevi Therapeutics.

Q

When is Trevi Therapeutics (NASDAQ:TRVI) reporting earnings?

A

Trevi Therapeutics does not have any upcoming earnings scheduled.

Q

Is Trevi Therapeutics (TRVI) going to split?

A

There is no upcoming split for Trevi Therapeutics.

Q

What sector and industry does Trevi Therapeutics (TRVI) operate in?

A

Trevi Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.